GSK3B and early-onset autosomal dominant Alzheimer disease: Despite experimental evidence supporting the therapeutic effect of GSK3β inhibition, none of GSK3β inhibitors was approved for treatment of diseases such as diabetes mellitus, Alzheimer's disease, and cancer.